Guiyang Xintian Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sales of Chinese patent drugs. The Company manufactures its products in the forms of capsules, mixture, granules, syrup, gel and tablets. The Companyâ€™s main products include Ningmitai Capsule, Kuntai Capsule, Kushen Gel and Xiaokucao Oral Liquid .The Company distributes its products in the domestic market.

Employees

1,388

Sector

Pharmaceuticals

Calendar

08-26 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
20/08/26	CN¥8.650	+2.73%	12,990,066
19/08/26	CN¥8.420	-0.12%	15,362,460
18/08/26	CN¥8.430	-1.86%	6,749,900
17/08/26	CN¥8.590	+2.26%	7,744,982
14/08/26	CN¥8.400	+0.72%	6,965,408

End-of-day quote Shenzhen S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. 20/08/2026			5-day change	1st Jan Change
8.650 ^CNY	+2.73%		+3.72%	-12.80%

05-08	Guiyang Xintian says key shareholder plans to unload up to about 3% stake	RE
04-29	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.04B 303M 259M 242M 222M 417M 28.95B 425M 2.87B 1.12B 14.51B 1.14B 1.11B 48.04B	P/E 2024	39.9x	P/E 2025	256x
Enterprise Value	2.53B 376M 322M 301M 276M 518M 36B 528M 3.57B 1.39B 18.04B 1.41B 1.38B 59.73B	EV / Sales 2024	3.07x	EV / Sales 2025	3.77x
Free-Float	64.83%	Yield 2024	1.06%	Yield 2025	0.3%

05-08	Guiyang Xintian says key shareholder plans to unload up to about 3% stake	RE
04-29	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-03	Guiyang Xintian Pharmaceutical to Offload Up to 2.4 Million Repurchased Shares	MT
03-30	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Guiyang Xintian Pharmaceutical Co.,Ltd. announces Annual dividend, payable on May 27, 2026	CI
03-27	Guiyang Xintian Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 300 million in funding	CI
30/10/25	Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
20/10/25	Xintian Pharma's controlling shareholder to cut stake	RE
15/10/25	Guiyang Xintian Pharmaceutical Gets China Clinical Trial Nod for Traditional Chemotherapy Supplemental Drug	MT
18/09/25	Guiyang Xintian Pharmaceutical Co.,Ltd. agreed to acquire an additional minority stake in Shanghai Huilun Life Sciences & Technology Co., Ltd. from Hubei Pinghu Venture Capital Co., Ltd. for CNY 20 million.	CI
18/09/25	Shanghai Huilun Life Sciences & Technology Co., Ltd. announced that it has received CNY 72 million in funding from Guiyang Xintian Pharmaceutical Co.,Ltd.	CI
04/09/25	Xintian Pharmaceutical Completes Setting Up Subsidiary	MT
21/08/25	Shanghai Huilun Life Sciences & Technology Co., Ltd. announced that it expects to receive CNY 72 million in funding from Guiyang Xintian Pharmaceutical Co.,Ltd. and other investors	CI

1 day	+2.73%
1 week	+3.72%
Current month	+12.63%
1 month	+12.48%
3 months	-10.18%
6 months	-17.70%
Current year	-12.80%

Guiyang Xintian Pharmaceutical Co.,Ltd. Stock

Stocks

002873

CNE100002QB5

Pharmaceuticals

Valuation: Guiyang Xintian Pharmaceutical Co.,Ltd.

Chart: Guiyang Xintian Pharmaceutical Co.,Ltd.

Latest news : Guiyang Xintian Pharmaceutical Co.,Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Guiyang Xintian Pharmaceutical Co.,Ltd.

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	8.13	8.96
1 month	7.1	8.96
Current year	7.04	13.09
1 year	7.04	14.02
3 years	7.04	15.19
5 years	7.04	20.12
10 years	6.63	20.12

Manager	Title	Age	Since
Da Lun Dong CEO	Chief Executive Officer	62	01/05/2005
Zhi Hui Zeng DFI	Director of Finance/CFO	53	04/11/2019
Zhong Lei He PRN	Corporate Officer/Principal	49	01/04/2021

Director	Title	Age	Since
Da Lun Dong CHM	Chairman	62	01/12/2001
Jin Hua Wang BRD	Director/Board Member	59	11/08/1995
Wen Yi Wang BRD	Director/Board Member	53	08/04/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIYANG XINTIAN PHARMACEUTICAL CO.,LTD.	+2.73%	+3.72%	-36.72%	-26.32%	303M
MERCK & CO., INC.	-2.11%	+9.92%	+75.99%	+36.44%	368B
MERCK KGAA	-0.22%	-1.04%	+23.65%	-13.20%	70.1B
HALOZYME THERAPEUTICS, INC.	-1.39%	+5.41%	+49.19%	+145.31%	12.04B
KYOWA KIRIN CO., LTD.	-2.19%	-0.45%	-2.38%	-0.58%	8.66B
SK BIOPHARMACEUTICALS CO., LTD.	+1.41%	-1.26%	-10.82%	0.00%	4.86B
YUHAN CORPORATION	+4.77%	+1.09%	-26.39%	+19.47%	4.46B
BETTA PHARMACEUTICALS CO., LTD.	+8.85%	-18.65%	-15.25%	+23.50%	3.48B
SUPERNUS PHARMACEUTICALS, INC.	-2.25%	+0.64%	+11.18%	+53.21%	2.76B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.95%	-2.83%	-8.04%	-4.20%	2.17B
Average	+1.16%	-0.18%	+6.04%	+23.36%	47.64B
Weighted average by Cap.	-1.61%	+7.50%	+62.84%	+30.46%

	2024	2025
Net sales	858M 127M 109M 102M 93.46M 176M 12.2B 179M 1.21B 471M 6.11B 479M 468M 20.24B	750M 111M 95.44M 89.04M 81.71M 154M 10.67B 157M 1.06B 412M 5.35B 419M 409M 17.7B
Net income	52.32M 7.78M 6.66M 6.21M 5.7M 10.71M 744M 10.93M 73.72M 28.74M 373M 29.21M 28.57M 1.24B	9.11M 1.35M 1.16M 1.08M 993K 1.87M 130M 1.9M 12.84M 5M 64.96M 5.09M 4.98M 215M
Net Debt	442M 65.7M 56.25M 52.48M 48.16M 90.5M 6.29B 92.28M 623M 243M 3.15B 247M 241M 10.43B	495M 73.61M 63.02M 58.8M 53.96M 101M 7.04B 103M 698M 272M 3.53B 276M 270M 11.69B